肿瘤细胞治疗研究
英文原题：Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
该患者获得完全缓解和数月的长期无病生存，目前仍在继续随访。
背景：间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤（ALK+ ALCL）是一种罕见的成熟T细胞非霍奇金淋巴瘤。一线化疗后复发或难治性ALCL患者预后极差。NCCN指南推荐强化化疗，可联合或不联合自体干细胞移植（ASCT）巩固，但该治疗并非对所有ALK+ ALCL患者都有效。 病例报告：本文报告一例复发/难治性ALK+ ALCL患者，先接受crizotinib和brentuximab vedotin桥接治疗，随后接受自体干细胞移植及序贯抗CD30 CAR-T细胞治疗。 结论：患者达到完全缓解并获得长期无病生存，随访仍在继续。本病例的联合治疗模式可为复发/难治性ALK+ ALCL管理提供参考，仍需进一步前瞻性试验验证疗效。
BACKGROUND: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare, mature T-cell non-Hodgkin lymphoma. The prognosis of patients with relapsed or refractory ALCL following first-line chemotherapy is extremely poor. NCCN guidelines recommend intensified chemotherapy with or without ASCT consolidation for r/r ALCL, however, this is not an effective treatment for all ALK+ALCL. CASE REPORT: Herein, we report a patient with relapsed/refractory ALK+ ALCL who received crizotinib and brentuximab vedotin as bridging therapy, followed by autologous stem cell transplantation and sequential anti-CD30 CAR T cell therapy. CONCLUSION: The patient achieved complete remission and long-term disease-free survival of months and continues to be followed up. The combination therapy model in this case may provide guidance for the management of relapsed/refractory ALK+ ALCL, and further prospective trials are needed to confirm its effectiveness.
MEMBER ACCOUNT
登录成功会直接打开下一页。
